E. Mikus

发表

Potential L-Type Voltage–Operated Calcium Channel Blocking Effect of Drotaverine on Functional Models

A. Guttman, Zoltán Patai, E. Mikus, 2016, The Journal of Pharmacology and Experimental Therapeutics.

Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 1st communication: in vivo demonstration of the effects on animal models of cough and of mucociliary clearance.

M. Pascal, V. Saano, P. Arányi, 1997, Arzneimittel-Forschung.

Biochemical and Pharmacological Characterization of 2-(9-(2-Piperidinoethoxy)-4-oxo-4H-pyrido[1,2-a]pyrimidin-2-yloxymethyl)-4-(1-methylethyl)-6-methoxy-1,2-benzisothiazol-3(2H)-one-1,1-dioxide (SSR69071), a Novel, Orally Active Elastase Inhibitor

T. Szabó, Márton Varga, P. Arányi, 2003, Journal of Pharmacology and Experimental Therapeutics.

Biochemical and pharmacological characterization of SSR 69071 , a novel orally active elastase inhibitor

T. Szabó, Márton Varga, P. Arányi, 2003 .

Cardioprotective effect of prostacyclin and 7-oxo-PGI2 in rats against chronic isoproterenol damage.

P. Körmöczy, E. Mikus, C. Vértesi, 1987, Prostaglandins.

Pulmonary , gastrointestinal and urogenital pharmacology Interaction of SSR 161421 , a novel specific adenosine A 3 receptor antagonist with adenosine A 3 receptor agonists both in vitro and in vivo

T. Szabó, A. Galzin, K. Gerber, 2013 .

Assessment of the Airway Smooth Muscle Relaxant Effect of Drotaverine

A. Guttman, Zoltán Patai, E. Mikus, 2018, Pharmacology.

Evaluation of SSR161421, a novel orally active adenosine A3 receptor antagonist on pharmacology models.

A. Galzin, M. Finet, P. Arányi, 2013, European journal of pharmacology.

Experimental studies on the antitussive properties of the new xanthine derivative 1H-purine-2,6-dione, 3,7-dihydro-3-methyl-7[(5-methyl-1,2,4-oxadiazol-3-yl)methyl]. 2nd communication: investigations on theophylline-like activities.

M. Pascal, F. Lacheretz, P. Arányi, 1997, Arzneimittel-Forschung.

Effect of novel adenosine A3 receptor antagonist SSR161421 in allergic sheep models

W. Abraham, A. Galzin, M. Finet, 2016 .

Pulmonary , gastrointestinal and urogenital pharmacology Evaluation of SSR 161421 , a novel orally active adenosine A 3 receptor antagonist on pharmacology models

A. Galzin, M. Finet, P. Arányi, 2013 .

A novel orally active inhibitor of HLE.

Márton Varga, P. Arányi, Katalin Urbán-Szabó, 2003, European journal of medicinal chemistry.

Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma

K. Gala, M. Wieczorek, Beata M Zygmunt, 2020, PloS one.

Experimental Studies on Guanosine 3’,5’-Cyclic Monophosphate Levels and Airway Responsiveness of the Novel Phosphodiesterase Type 5 Inhibitor

J. Herbert, M. Pascal, P. Schaeffer, 1999, Arzneimittelforschung.